INIS
doses
100%
applications
100%
administration
100%
range
100%
pharmacology
100%
reduction
50%
drugs
50%
symptoms
50%
resources
50%
receptors
50%
comparative evaluations
50%
safety
50%
clinical trials
50%
inflammation
50%
peaks
50%
affinity
50%
surveys
50%
sustainability
50%
amplification
50%
dissolution
50%
tryptamines
50%
Keyphrases
Potential Therapeutics
100%
Clinical Potential
100%
Clinical Pharmacology
100%
Therapeutic Use
100%
5-methoxy-N,N-dimethyltryptamine
100%
Emotional State
18%
Individualized Dosing
18%
5-HT1A
18%
Psychedelics
18%
Clinical Trials
9%
Depressive Symptoms
9%
Auditory Perception
9%
Time Perception
9%
Therapeutic Efficacy
9%
Anxiety Symptoms
9%
Anxiety-depression
9%
Inflammatory Process
9%
Dose Finding
9%
Mental Health Outcomes
9%
Rapid Onset
9%
Dose Escalation
9%
Route of Administration
9%
Changes in Mental Health
9%
5-HT2A Receptor
9%
Neural Mechanisms
9%
Clinical Effect
9%
Stress Symptoms
9%
Subjective Effects
9%
Drug Development Program
9%
Multiple Exposures
9%
Medical Indications
9%
Commercial Development
9%
Neuroendocrine Function
9%
Peak Experience
9%
Immunoregulation
9%
Tryptamine
9%
Ego Dissolution
9%
Biotechnology Firms
9%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Pharmacology
100%
N,N-Dimethyltryptamine
100%
Psychotomimetic
18%
Inflammation
9%
Receptor
9%
Clinical Trial
9%
Anti-Inflammatory Drug
9%
Drug Development
9%
Observational Study
9%
Combination Therapy
9%
Route of Administration
9%
Subjective Effects
9%
Tryptamine
9%